MedAI Verdict
All comparisons

Proscia Concentriq vs Tempus Digital Pathology

Proscia Concentriq and Tempus Digital Pathology both compete in pathology, but answer different questions. Proscia Concentriq is our pick for pharma R&D labs: Used by 16/20 top pharma. $130M total funding. Tempus Digital Pathology earns the Paige acquisition (Aug 2025) slot: Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI. The right choice depends on whether your priority is pharma r&d labs or paige acquisition (aug 2025).

Category
Pathology
Tools compared
02
Reviewed
October 20, 2026
Editorial silo
/best-ai-pathology

The two contenders

Best for pharma R&D labs

Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.

Pricing
No public price. Demo request only.
Compliance
FDA 510(k) / SOC 2 Type II (vendor announcement, 2025-12-03) / ISO 27001 (vendor-stated, 2023)

Best after Paige acquisition (Aug 2025)

Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.

Pricing
No public price on the Tempus pages.
Compliance
FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer) / CE-IVDR

Side-by-side specifications

How Proscia Concentriq and Tempus Digital Pathology compare

Pricing, compliance, and integrations sourced from vendor documentation. Verified October 20, 2026.

SpecProscia ConcentriqTempus Digital Pathology
PricingNo public price. Demo request only.No public price on the Tempus pages.
Free tierNo / unverifiedNo / unverified
HIPAANo / unverifiedNo / unverified
SOC 2 Type IIYesNo / unverified
EHR integrationsNot specifiedNot specified
Founded——
HQ—US
Best forBest for pharma R&D labsBest after Paige acquisition (Aug 2025)

Scroll horizontally to see both columns.

Editorial verdict

When to pick each one

When to pick Proscia Concentriq

Best for pharma R&D labs

Used by 16/20 top pharma. $130M total funding.

  • IMS platform + AI marketplace
  • Strongest pharma R&D footprint
Read the full Proscia Concentriq review

When to pick Tempus Digital Pathology

Best after Paige acquisition (Aug 2025)

Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.

  • NASDAQ:TEM
  • Most clinical-validation depth
  • FDA + CE-IVDR cleared modules
Read the full Tempus Digital Pathology review

Wider context

Open the full pathology comparison

Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.

See all pathology

/best-ai-pathology